NCT05226780终止2 期
A Prospective, Long-Term, Interventional, Active Extension Study to Evaluate the Safety and Tolerability of NBI-921352 as Adjunctive Therapy in Subjects With SCN8A Developmental and Epileptic Encephalopathy Syndrome (SCN8A-DEE)
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 入组人数
- 8
- 试验地点
- 8
- 主要终点
- The participant incidence of serious treatment-emergent adverse events (TEAEs), TEAEs leading to discontinuation of study treatment, and fatal TEAEs
研究概览
简要总结
Extension study to evaluate how safe and tolerable the drug NBI-921352 is when used as adjunctive therapy in participants with SCN8A developmental and epileptic encephalopathy syndrome (SCN8A-DEE).
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 2 Years 至 22 Years（Child, Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •For Participants Who Participated in NBI-921352-DEE2012:
- •Written or oral pediatric assent from the participant and written informed consent from the participant's parent(s) or legal guardian(s) for pediatric participants and adult participants who are not capable of providing consent. Adult participant who are ≥18 years of age and capable of providing consent should sign an Informed Consent Form (ICF).
- •Completed 16 weeks of treatment in Study NBI-921352-DEE
- •Continue to use a nocturnal alerting system or practice consistent with standards of care for the duration of the study.
- •Have an adequate rescue medication regimen per the investigator's judgment in place for the duration of the study.
- •For Participants Who did not Participate in NBI-921352-DEE2012:
- •Written or oral pediatric assent from the participant if deemed capable of providing assent and written informed consent from the participant's parent(s) or legal guardian(s) for pediatric participants and for adult participants who are not capable of providing consent. Adult participants who are capable of providing consent should sign an ICF.
- •Be a male or female 2 to 21 years of age, inclusive.
- •Have a diagnosis of SCN8A-DEE supported by both clinical and genetic findings.
- •Have on average at least 1 countable motor seizure per week and not be seizure-free for more than 20 consecutive days.
- •Being treated with at least 1 other antiseizure medication (ASM), but no more than 4 ASMs.
- •Have failed to achieve seizure freedom with at least 2 ASMs.
- •Have a body weight of at least 10 kilograms.
排除标准
- •For Participants Who Participated in NBI-921352-DEE2012:
- •- Have developed any other disorder for which the treatment takes priority over treatment of SCN8A-DEE or is likely to interfere with study treatment or impair treatment compliance.
- •For Participants Who did not Participate in NBI-921352-DEE2012:
- •Have symptoms that would be more consistent with another epilepsy disorder such as Dravet syndrome (for example, fever-induced episodes of status epilepticus, frequent myoclonic seizures, worsening on sodium channel blockers, absence seizures with generalized spike-and-wave electroencephalogram [EEG] as the sole seizure type).
- •Currently receiving cannabinoids or medical marijuana except Epidiolex/Epidyolex, unless approved by the Sponsor.
- •Currently taking systemic steroids (excluding inhaled medication for asthma treatments and intranasal steroids for allergies) such as adrenocorticotropin hormone, high-dose prednisolone for epileptic spasms. If participant has received these medications in the past, they must be off these medications for at least 3 months prior to the screening visit and these drugs may not be initiated during the duration of the study. Intermittent steroids to treat non-epilepsy-related diseases (such as allergies or dermatological conditions) are not exclusionary.
- •Have a history of moderate or severe head trauma or other neurological disorders or systemic medical diseases that are, in the investigator's opinion, likely to affect nervous system functioning.
- •Have a clinically significant medical condition or chronic disease, that in the opinion of the investigator would preclude the participant from participating in and completing the study or that could confound interpretation of study outcome.
- •Have clinically significant abnormal vital signs at the screening visit, as determined by the investigator.
- •Have one or more clinical laboratory test values outside the reference range, based on blood samples taken at the screening visit, that are of potential risk to the participants safety as determined by the investigator.
- •Have, at the screening visit, an electrocardiogram (ECG) finding of a corrected QT interval using Fridericia's formula (QTcF) > 450 milliseconds (msec) or presence of any significant cardiac abnormality.
研究组 & 干预措施
NBI-921352
Experimental
NBI-921352 administered for up to 164 weeks.
干预措施: NBI-921352 (Drug)
结局指标
主要结局
The participant incidence of serious treatment-emergent adverse events (TEAEs), TEAEs leading to discontinuation of study treatment, and fatal TEAEs
时间窗: Day 1 to Week 168
次要结局
- Percentage change from baseline in 28-day seizure frequency for countable motor seizures(Baseline, up to Week 162)
研究者
研究点 (8)
Loading locations...
相似试验
已完成
2 期
Phase II BGG492 Capsule Extension for Partial EpilepsyPartial Onset SeizuresNCT01338805Novartis Pharmaceuticals56
已完成
2 期
NBI-98854 Dose Titration Study for the Treatment of Tardive DyskinesiaTardive DyskinesiaNCT01733121Neurocrine Biosciences102
终止
2 期
Study to Evaluate NBI-921352 as Adjunctive Therapy in Subjects With SCN8A Developmental and Epileptic Encephalopathy Syndrome (SCN8A-DEE)SCN8A Developmental and Epileptic Encephalopathy SyndromeNCT04873869Neurocrine Biosciences8
已完成
3 期
Efficacy and Safety Study of BIA 2-093 in Combination With Other Anti-Epileptic Drugs to Treat Partial EpilepsyPartial EpilepsyNCT00957047Bial - Portela C S.A.395
已完成
3 期
Efficacy and Safety of Eslicarbazepine Acetate as Adjunctive Therapy for Refractory Partial EpilepsyPartial EpilepsyNCT00957372Bial - Portela C S.A.253